Oestrogen receptor-mediated expression of Olfactomedin 4 regulates the progression of endometrial adenocarcinoma.
Bottom Line: The mechanism of OLFM4 in tumuorigenesis is elusive.Down-regulation of OLFM4 was associated with decreased cumulative survival rate of patients with endometrioid adenocarcinoma.Our data suggested that impairment of ERα signal-mediated OLFM4 expression promoted the malignant progression of endometrioid adenocarcinoma, which may have significance for the therapy of this carcinoma.
Affiliation: Department of Pathology, The First Affiliated Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, China.Show MeSH
Related in: MedlinePlus
Mentions: To confirm the in silico analysis, we assessed the expression of OLFM4 in normal endometrium, precancerous endometrial tissue and endometrial cancer using IHC. Olfactomedin 4 proteins were stained in the cytoplasm of glandular cells (Fig. 1). The rates of OLFM4 high-expression in normal endometrium, endometrial hyperplasia without or with atypia, and endometrioid adenocarcinoma were 43.3, 60.0, 66.7 and 68.0%, respectively (Table S4). The OLFM4 expression level in endometrioid adenocarcinoma was significantly higher than in normal endometrium (P = 0.008), indicating that OLFM4 expression is up-regulated in endometrial carcinogenesis. Similar to what was observed with IHC, the OLFM4 mRNA level detected by real-time PCR in endometrial hyperplasia and endometrioid adenocarcinomas was higher than that in normal endometrium (P < 0.017, Fig. 2A).
Affiliation: Department of Pathology, The First Affiliated Hospital, Sun Yat-sen (Zhongshan) University, Guangzhou, China.